Suppr超能文献

冠心病患者抑郁的筛查、转诊和治疗。

Screening, referral and treatment for depression in patients with coronary heart disease.

机构信息

University of Queensland, Brisbane, QLD, Australia.

出版信息

Med J Aust. 2013 May 20;198(9):483-4. doi: 10.5694/mja13.10153.

Abstract

In 2003, the National Heart Foundation of Australia position statement on "stress" and heart disease found that depression was an important risk factor for coronary heart disease (CHD). This 2013 statement updates the evidence on depression (mild, moderate and severe) in patients with CHD, and provides guidance for health professionals on screening and treatment for depression in patients with CHD. The prevalence of depression is high in patients with CHD and it has a significant impact on the patient's quality of life and adherence to therapy, and an independent effect on prognosis. Rates of major depressive disorder of around 15% have been reported in patients after myocardial infarction or coronary artery bypass grafting. To provide the best possible care, it is important to recognise depression in patients with CHD. Routine screening for depression in all patients with CHD is indicated at first presentation, and again at the next follow-up appointment. A follow-up screen should occur 2-3 months after a CHD event. Screening should then be considered on a yearly basis, as for any other major risk factor for CHD. A simple tool for initial screening, such as the Patient Health Questionnaire-2 (PHQ-2) or the short-form Cardiac Depression Scale (CDS), can be incorporated into usual clinical practice with minimum interference, and may increase uptake of screening. Patients with positive screening results may need further evaluation. Appropriate treatment should be commenced, and the patient monitored. If screening is followed by comprehensive care, depression outcomes are likely to be improved. Patients with CHD and depression respond to cognitive behaviour therapy, collaborative care, exercise and some drug therapies in a similar way to the general population. However, tricyclic antidepressant drugs may worsen CHD outcomes and should be avoided. Coordination of care between health care providers is essential for optimal outcomes for patients. The benefits of treating depression include improved quality of life, improved adherence to other therapies and, potentially, improved CHD outcomes.

摘要

2003 年,澳大利亚国家心脏基金会关于“压力”与心脏病的立场声明发现,抑郁是冠心病(CHD)的一个重要危险因素。这份 2013 年的声明更新了冠心病患者轻度、中度和重度抑郁的证据,并为心脏科医生在冠心病患者中筛查和治疗抑郁提供了指导。冠心病患者中抑郁的患病率很高,对患者的生活质量和治疗依从性有重大影响,并对预后有独立影响。心肌梗死后或冠状动脉旁路移植术后患者的重度抑郁障碍发生率约为 15%。为了提供尽可能好的护理,识别冠心病患者的抑郁很重要。所有冠心病患者初次就诊时都应进行常规抑郁筛查,下次随访时也应进行。CHD 事件发生后 2-3 个月应进行随访筛查。之后,应每年进行一次筛查,就像筛查其他冠心病主要危险因素一样。一种简单的初始筛查工具,如患者健康问卷-2(PHQ-2)或简短版心脏抑郁量表(CDS),可最小程度干扰地纳入常规临床实践,可能会增加筛查的参与度。筛查阳性的患者可能需要进一步评估。应开始适当的治疗,并对患者进行监测。如果筛查后进行全面护理,抑郁结局可能会改善。冠心病伴抑郁的患者对认知行为疗法、协作护理、运动和某些药物治疗的反应与一般人群相似。然而,三环类抗抑郁药可能会加重 CHD 结局,应避免使用。医疗保健提供者之间的护理协调对于患者的最佳结果至关重要。治疗抑郁的益处包括提高生活质量、提高对其他治疗的依从性,以及可能改善 CHD 结局。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验